Compare Hims and Hers Health Inc (HIMS) vs Kyndryl Holdings Inc (KD) Price & Performance

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.

Kyndryl Holdings (KD) trades at $11.45, down 0.26% on the day, with technical indicators showing bearish momentum. The company reported mixed quarterly results, missing Q4 2025 and Q1 2026 EPS estimates but beating in Q2 2026. Recent financials show improved profitability with 2025 net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B in 2025. Analyst sentiment is cautious with a consensus 'Hold' rating and $14.67 price target, while institutional activity includes recent purchases by Virginia Retirement Systems.

KD presents a turnaround story with improving profitability but faces revenue headwinds and competitive pressures. The stock trades at reasonable valuation multiples (P/E 30.95, P/S 0.18) with positive cash flow generation. Key risks include ongoing revenue declines and high debt levels, while opportunities exist in AI initiatives and government contracts. The current technical weakness may present entry points for patient investors betting on management's execution.